Genetic Blind Spot: Mayo Clinic Study reveals Widespread Undiagnosed High Cholesterol Risk
Table of Contents
A new study reveals that current genetic screening guidelines are failing to identify teh vast majority of individuals with familial hypercholesterolemia (FH), a common inherited condition that dramatically increases the risk of early heart disease and stroke. The findings underscore a critical gap in preventative cardiovascular care and highlight the potential of expanded genetic testing to save lives.
Cardiovascular disease remains the leading cause of death in the United States, impacting millions annually and encompassing conditions like coronary artery disease, heart failure, and stroke. High cholesterol is a major contributing factor,and FH,often silent for years within families,significantly elevates that risk.
Researchers at the Mayo Clinic discovered that nearly 90% of participants with FH would have been missed by standard genetic testing protocols. This startling statistic emerged from an analysis of data collected through the Tapestry DNA research study, a large, population-based initiative aimed at integrating genomics into routine medical practice. The study, published in circulation: Genomic and Precision Medicine, involved more than 84,000 individuals across Mayo Clinic locations in Arizona, Florida, and Minnesota.
Approximately one in five participants identified with FH had already developed coronary artery disease, emphasizing the urgent need for earlier detection.”Our findings expose a blind spot in current national guidelines, which rely on cholesterol levels and family history to determine who should receive genetic testing,” explained Niloy Jewel Samadder, M.D., the study’s lead author and a Mayo Clinic gastroenterologist and cancer geneticist. “If we can find those at risk of cardiovascular disease early, we can treat it early and change its course and likely save lives.”
Exome Sequencing Uncovers Genetic Risk
The research team utilized exome sequencing, a technique that examines the protein-coding regions of the genome – the areas most likely to harbor disease-causing mutations. Through this extensive analysis, they identified 419 individuals carrying genetic variants associated with FH. Crucially, nearly 75% of these individuals would not have been flagged for testing based on existing clinical criteria.
FH affects an estimated 1 in 200 to 250 people worldwide, leading to dangerously high levels of low-density lipoprotein (LDL) cholesterol – often referred to as “bad” cholesterol – from birth. Effective treatments are available, but their benefit is contingent on timely diagnosis.
The Future of Preventative Cardiology
The study strongly advocates for a shift towards incorporating genetic screening into everyday medical care. This proactive approach would enable the identification of high-risk individuals before they experience cardiovascular events.
This initiative aligns with Mayo Clinic’s “Precure” strategic priority, a c
Expanded Article – Substantive News Report
Why: The Mayo Clinic study was conducted to assess the effectiveness of current genetic screening guidelines for familial hypercholesterolemia (FH). Researchers found that existing protocols miss the vast majority of individuals with FH, leading to delayed diagnosis and increased risk of cardiovascular events.
Who: The study was led by Niloy Jewel Samadder, M.D., a gastroenterologist and cancer geneticist at the Mayo Clinic. The research involved a team at Mayo Clinic locations in Arizona, Florida, and Minnesota, and analyzed data from